Printer Friendly

Hypnotic sleep aids.

The physical discomforts of pregnancy induced by the surge of progesterone and the expanding uterus can result in sleep deprivation in pregnancy. An increased need to urinate, nausea and vomiting, heartburn, difficulty in finding a comfortable sleeping position, and, as the pregnancy progresses, the kicking and movement of the fetus, all conspire against a good night's sleep.

Prescribing sleeping medications in pregnancy may not be the best solution because long-term use can lead to habituation in the woman and her fetus. But patients often seek drug therapy to help them sleep, so it is essential to know what is relatively safe and what is not. Hypnotics fall into five subclasses:

* Oral barbiturates. Included in this group are aprobarbital (pregnancy risk factor C) (Alurate); pentobarbital (D) (Nembutal); and secobarbital (D) (Seconal). Developmental toxicity has not been proven, but more studies are needed regarding the potential for behavioral toxicity after long-term in utero exposure.

Their long elimination half-lives (24, 22-50, and 28 hours, respectively) can cause prolonged sedation, or hangover. They are controlled substances with potential for abuse, which makes them more difficult to prescribe.

Although they are excreted into milk in low amounts, they can be classified as compatible with breast-feeding.

* Benzodiazepines. Estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), and temazepam (Restoril) are in this category Data on using these agents in pregnancy are limited. Although there has been no proven association between any of these agents and birth defects, they probably have effects on the embryo or fetus similar to diazepam (Valium), including neonatal motor depression (floppy infant syndrome) and/or withdrawal if used in the third trimester.

Moreover, all four agents are categorized as contraindicated (risk factor X) by their manufacturers, so they should not be prescribed. Small amounts of quazepam and temazepam are excreted into milk, and the other two agents are most likely in milk as well. Occasional dosing during breast-feeding is probably safe, but the long-term effects on a nursing infant are unknown.

* Nonbenzodiazepines. There are five drugs in this category: chloral hydrate (for example, Somnote), ramelteon (Rozerem), zaleplon (Sonata), and low-dose (25-75 mg) trazodone (Desyrel), all risk factor C, and zolpidem (Ambien), risk factor B.

The use for sleep of the antidepressant trazodone is off label, but the drug is sometimes combined with other antidepressants for this purpose.

As with the benzodiazepines, the human pregnancy data are limited or nonexistent. There are no animal data for chloral hydrate, an old product that is now rarely used, but animal data on the other nonbenzodiazepines suggest low risk in pregnancy. But, as with most drugs, the best course is to avoid them in the first trimester.

Occasional use in the second and third trimesters probably is low risk, but long-term use (more than 4 weeks) should be avoided. Small amounts of these drugs are excreted into milk, but occasional, short-term use probably is compatible with breast-feeding.

* OTC antihistamines. There are two in this category, diphenhydramine (such as Benadryl), and doxylamine (Unisom Nighttime Sleep Aid). Diphenhydramine (risk factor B) is safe throughout gestation, as is doxylamine (risk factor A). A major advantage of these antihistamines is that both have antiemetic properties that can reduce pregnancy-induced nausea and vomiting. If pyridoxine (vitamin [B.sub.[sigma]]) is taken with doxylamine, the combination is the antiemetic most frequently studied in pregnancy.

There is little or no experience with these agents during lactation. Although some manufacturers consider them contraindicated during breast-feeding, the lack of toxicity reports suggests these antihistamines probably are low risk for full-term nursing infants.

* Natural products. About 50 natural products are or have been advocated for sleep, but few have enough data to recommend their use in pregnancy or lactation. Moreover, the content and purity of natural products are often unregulated.

Natural agents that seem to be low risk are ginseng (not Siberian), honey, nutmeg, oats, and St. John's wort. But note that ginseng can cause hypertension and hypoglycemia.

Agents to be avoided include American hellebore, butterbur or other petasites, kava, marijuana, melatonin (available only as an orphan drug in the United States), mugwort, passion flower, quassia, rauwolfia, Siberian ginseng, taumelloolch, tulip tree, and valerian.

A nonpharmacologic approach is the best and safest course for pregnant patients with insomnia. If medications are required, occasional, short-term use is recommended; one of the OTC antihistamines is probably best.

A nonbenzodiazepine agent, such as zolpidem, would be my second choice. For more information, visit www.babycenter.com, a Web site frequently visited by women to obtain information about their pregnancies, including tips on sleeping well.

MR. BRIGGS is pharmacist clinical specialist, Women's Pavilion, Miller Children's Hospital, Long Beach, Calif.; clinical professor of pharmacy, University of California, San Francisco; and adjunct professor of pharmacy, University of Southern California, Los Angeles. He is also a fellow of the American College of Clinical Pharmacy and coauthor of the reference book "Drugs in Pregnancy and Lactation."

BY GERALD G. BRIGGS, B. PHARM., FCCP
COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DRUGS, PREGNANCY, AND LACTATION
Author:Briggs, Gerald G.
Publication:Internal Medicine News
Geographic Code:1USA
Date:Jul 15, 2007
Words:816
Previous Article:Data tie valproate to risk of birth defects.
Next Article:AHA spearheads STEMI response initiative; 'Mission: lifeline' aims to improve public education and develop treatment and accountability protocols.
Topics:


Related Articles
Staring into the dark: research investigates insomnia drugs.
Hypnotics may prove protective against falls.
Antihyperlipidemic agents.
Program helps insomniacs quit hypnotics.
Gastrointestinal agents: Part III.
Vaccines in pregnancy and lactation.
FDA approves 13 generic Ambien formulations.
FDA considers changes to drug label pregnancy info.
FDA to revise pregnancy category labeling.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters